Teladoc shares surge 9% on narrower-than-feared loss, raised outlook
Teladoc Health (TDOC) shares rose 9% after Q3 results beat expectations with a loss of -$0.15 per share vs. -$0.22 estimate, and revenue of $605.1M vs. $588.44M estimate. The company raised its full-year outlook, projecting a loss of -$0.75 to -$0.95 per share and revenue of $2.4B to $2.44B. Adjusted EBITDA increased 14% YoY to $79.4M, with the Integrated Care segment showing growth while BetterHelp declined 13% YoY.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst for traders, indicating possible continued momentum in the stock.
Market read
First‑report earnings release with material beat and guidance upgrade, driving a 9% price move; high relevance for short‑term traders.
What to watch
Potential headwinds from insurance reimbursement rates and competition could limit upside despite the current beat.
Background
Teladoc Health reported Q3 2026 results, beating consensus and raising its full‑year outlook, leading to a notable share price increase.
Ticker impact
Q3 results beat expectations and raised full-year outlook, driving a 9% share surge.
likely upward pressure as investors price in better-than-expected earnings and higher revenue guidance
The company posted a loss of $0.15 vs $0.22 consensus and revenue of $605.1M above estimates, then lifted its FY loss guidance range and revenue outlook, prompting a 9% jump.
Market effects
Virtual‑care and telehealth peers may see short‑term rally on improved outlook for the segment.
U.S. healthcare stocks could benefit from the positive earnings surprise.
Limited to U.S. and global telehealth investors; no broader macro effect.
Counterpoint
The BetterHelp segment still shows revenue decline, suggesting underlying demand challenges that could weigh on future performance.
Key entities
- companyTeladoc Health Inc.
U.S. listed virtual‑care provider (NYSE:TDOC).
- executiveChuck Divita
CEO of Teladoc who commented on the results.
